子宫内膜异位症类器官:前景与挑战
本文为评论文章,讨论可用于研究子宫内膜异位症的体内与体外系统,重点介绍近期开发的人子宫内膜异位症类器官作为前沿研究模型,阐述其优势并描述建立可靠体外模型需解决的挑战,同时讨论微流控技术与CRISPR技术的应用前景。
要点
- 子宫内膜异位症影响全球10-15%女性,目前无根治方法且现有治疗并非总是有效。
- 激素失调可能参与炎症、血管生成、子宫内膜容受性不良、胚胎着床失败和不孕。
- 人子宫内膜异位症类器官是前沿研究模型,但需解决挑战才能成为可靠体外模型。
核心结论
- 人子宫内膜异位症类器官是前沿且创新的研究模型,但需解决相关挑战才能产生可靠的体外人子宫内膜异位症模型。
研究设计与样本
- 本文为评论文章,讨论用于研究子宫内膜异位症的体内与体外系统。
主要发现
- 子宫内膜异位症影响全球10-15%女性,目前无根治方法且现有治疗并非总是有效。
- 激素失调可能参与子宫内膜异位症女性的炎症、血管生成、子宫内膜容受性不良、胚胎着床失败和不孕。
- 关于激素失调可能原因的相关性证据存在,但功能机制仍未知。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endometriosis is a sex hormone-dependent, painful disease that affects 10-15% of women worldwide with no definitive cure, and current treatments are not always effective. This limitation is mainly due to gaps in our knowledge about the mechanisms involved in the pathogenesis of endometriosis at the cellular and molecular levels. Hormonal dysregulation appears to be responsible for inflammation, angiogenesis, endometrial non-receptivity, embryo implantation failure and infertility in women with endometriosis. Although correlative evidence about possible causes of hormonal dysregulations exists, the functional mechanisms remain unknown. Reliable research models of endometriosis are needed to investigate the exact mechanisms that underlie hormone disruptions. This Commentary discusses the available in-vivo and in-vitro systems for studying endometriosis. The authors emphasize the recently developed human endometriosis organoids as cutting-edge and innovative research models for endometriosis investigations, discuss their advantages and describe challenges that must be addressed to yield a reliable in-vitro model of human endometriosis. Moreover, it discusses microfluidic technology to address the present challenges for producing advanced endometriosis organoids and how to benefit from CRISPR technology to improve our knowledge about disturbed hormonal function in patients with endometriosis.
引用
- Esfandiari F, Mansouri N, Shahhoseini M, et al. Endometriosis organoids: prospects and challenges. Reprod Biomed Online. 2022. PMID: 35562236. doi:10.1016/j.rbmo.2022.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。